MORE►
therapies
Osteal Therapeutics Chairman and CEO David Thompson spoke on the company's lead candidate at LSI Europe ‘23 Emerging Medtech Summit last fall.
Dallas Biotech Secures $50M Series D Funding To Combat Rare Hidden Killer in Joint Replacements
by Quincy Preston | Jul 16, 2024
The $50 million funding will support the commercial launch of Osteal Therapeutics' pioneering combination drug/device therapy targeting biofilm infections, which are notoriously difficult to eradicate.
by Lauren Hawkins |
Jul 21, 2020
Nanoscope Therapeutics, a TechFW client, has closed an over-subscribed Series A funding round for its leading work on retinas, which could enable the blind to see.
In addition, Nanoscope has named Al Guillem as Chairman of the Board. Guillem (pictured below) was part of TechFW's greatest success story when ZS Pharma, a company he co-founded, was purchased by AstraZeneca for $2.7 billion.
In addition, Nanoscope has named Al Guillem as Chairman of the Board. Guillem (pictured below) was part of TechFW's greatest success story when ZS Pharma, a company he co-founded, was purchased by AstraZeneca for $2.7 billion.
MORE►
